Brentuximab vedotin (BV) versus physician's choice (PC) of methotrexate or bexarotene in adult patients with previously treated CD30-positive cutaneous T-cell lymphoma (CTCL; mycosis fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL]): Final time to next therapy (TTNT) results from the phase 3 ALCANZA study Meeting Abstract
| Authors: | Scarisbrick, J.; Horwitz, S. M.; Prince, H. M.; Whittaker, S.; Duvic, M.; Kim, Y. H.; Quaglino, P.; Zinzani, P. L.; Bechter, O.; Eradat, H.; Pinter-Brown, L.; Akilov, O.; Geskin, L.; Sanches, J.; Ortiz-Romero, P.; Lisano, J.; Brown, L.; Bunn, V.; Little, M.; Dummer, R. |
| Abstract Title: | Brentuximab vedotin (BV) versus physician's choice (PC) of methotrexate or bexarotene in adult patients with previously treated CD30-positive cutaneous T-cell lymphoma (CTCL; mycosis fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL]): Final time to next therapy (TTNT) results from the phase 3 ALCANZA study |
| Meeting Title: | EORTC-CLTF 2019 Meeting on Cutaneous Lymphoma: Insights in Research and Patient Care |
| Journal Title: | European Journal of Cancer |
| Volume: | 119 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Sep 26-28 |
| Meeting Location: | Athens, Greece |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2019-01-01 |
| Start Page: | S31 |
| Language: | English |
| ACCESSION: | WOS:000508019000083 |
| PROVIDER: | wos |
| DOI: | 10.1016/S0959-8049(19)30595-7 |
| Notes: | Meeting Abstract: 085 -- Source: Wos |
